Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients

Melissa R. Laub, Stacy A. Crow, Heather A. Personett, Ross Dierkhising, Barry Boilson, Raymund R Razonable

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Tacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non-systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described. Methods: To assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole. Results: The median percent tacrolimus dose change was an increase of 66.7% (IQR 28.6%, 100%) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5% (IQR −52.3%, −30.9%). Five cases of allograft rejection were observed. Conclusion: In conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single-center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.

Original languageEnglish (US)
JournalTransplant Infectious Disease
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Clotrimazole
Tacrolimus
Oral Candidiasis
Transplant Recipients
Heart Transplantation
Immunosuppression
Intestines
Allografts
Transplantation

Keywords

  • clotrimazole
  • heart transplant
  • prophylaxis
  • tacrolimus
  • thrush

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients. / Laub, Melissa R.; Crow, Stacy A.; Personett, Heather A.; Dierkhising, Ross; Boilson, Barry; Razonable, Raymund R.

In: Transplant Infectious Disease, 01.01.2018.

Research output: Contribution to journalArticle

Laub, Melissa R. ; Crow, Stacy A. ; Personett, Heather A. ; Dierkhising, Ross ; Boilson, Barry ; Razonable, Raymund R. / Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients. In: Transplant Infectious Disease. 2018.
@article{f69b436b50c84ca5ab798ae1b3bcb546,
title = "Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients",
abstract = "Background: Tacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non-systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described. Methods: To assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole. Results: The median percent tacrolimus dose change was an increase of 66.7{\%} (IQR 28.6{\%}, 100{\%}) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5{\%} (IQR −52.3{\%}, −30.9{\%}). Five cases of allograft rejection were observed. Conclusion: In conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single-center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.",
keywords = "clotrimazole, heart transplant, prophylaxis, tacrolimus, thrush",
author = "Laub, {Melissa R.} and Crow, {Stacy A.} and Personett, {Heather A.} and Ross Dierkhising and Barry Boilson and Razonable, {Raymund R}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/tid.12979",
language = "English (US)",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients

AU - Laub, Melissa R.

AU - Crow, Stacy A.

AU - Personett, Heather A.

AU - Dierkhising, Ross

AU - Boilson, Barry

AU - Razonable, Raymund R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Tacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non-systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described. Methods: To assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole. Results: The median percent tacrolimus dose change was an increase of 66.7% (IQR 28.6%, 100%) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5% (IQR −52.3%, −30.9%). Five cases of allograft rejection were observed. Conclusion: In conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single-center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.

AB - Background: Tacrolimus is a cornerstone of immunosuppression after transplantation but is highly susceptible to changes from interacting variables and has a narrow therapeutic index. Clotrimazole troches are commonly used as a non-systemic antifungal to prevent oral candidiasis. Studies suggest that clotrimazole troches, though minimally absorbed systemically, may affect tacrolimus concentrations by inhibition of metabolic enzyme activity in the intestines. However, the magnitude of the impact of clotrimazole on tacrolimus dosing requirements to maintain goal levels is not well described. Methods: To assess this, tacrolimus dose adjustments and trough concentrations were retrospectively examined in 95 heart transplant recipients before and after the discontinuation of clotrimazole. Results: The median percent tacrolimus dose change was an increase of 66.7% (IQR 28.6%, 100%) after clotrimazole discontinuation, and the median trough concentration percent change from baseline to the first trough after clotrimazole discontinuation (in the absence of a dose change) was −42.5% (IQR −52.3%, −30.9%). Five cases of allograft rejection were observed. Conclusion: In conclusion, clotrimazole troches exert a meaningful interaction with tacrolimus that requires close monitoring and dose adjustment. The data from this single-center study provide novel information that could guide providers on the degree of tacrolimus dose adjustment needed when discontinuing clotrimazole prophylaxis after heart transplantation.

KW - clotrimazole

KW - heart transplant

KW - prophylaxis

KW - tacrolimus

KW - thrush

UR - http://www.scopus.com/inward/record.url?scp=85052946497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052946497&partnerID=8YFLogxK

U2 - 10.1111/tid.12979

DO - 10.1111/tid.12979

M3 - Article

C2 - 30120865

AN - SCOPUS:85052946497

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

ER -